InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
6
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-44.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Smiley Joshua L, See Remarks. Officer active across 1 company, notably Zai Lab Ltd. In total, 13 filings have been logged. Split: 6 buys · 2 sells. Total volume traded: €952k. History available since 16 November 2023. The latest transaction was filed on 6 April 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations13 total
3,017 shares@ US$20.4480.0023% mcap8.9% of flowAmerican Depositary SharesSEC:0000905148-26-001607:0
3,017 shares@ US$20.4480.0026% mcap8.9% of flowAmerican Depositary SharesSEC:0000905148-26-001607
10,000 shares@ US$28.910.011% mcap41.1% of flowAmerican Depositary SharesSEC:0000905148-25-003326:0
Ideal exit: 7 Jun 2026 (T+270)
10,000 shares@ US$28.9141.1% of flowAmerican Depositary SharesSEC:0000905148-25-003326
Ideal exit: 7 Jun 2026 (T+270)
7,145 sharesAmerican Depositary SharesSEC:0000905148-25-001117:0
32,062 sharesAmerican Depositary SharesSEC:0000905148-25-001077:0
15,900 sharesAmerican Depositary SharesSEC:0000905148-24-002290:0
3,000 shares@ US$21.405.6% of flowAmerican Depositary SharesSEC:0000905148-24-001418:0
Ideal exit: 7 Feb 2025 (T+270)
7,145 shares@ US$15.909.9% of flowAmerican Depositary SharesSEC:0000905148-24-001114:0
3,000 shares@ US$20.835.5% of flowAmerican Depositary SharesSEC:0000905148-24-000853:0
Ideal exit: 26 Nov 2024 (T+270)
4,000 shares@ US$29.9010.4% of flowAmerican Depositary SharesSEC:0000905148-23-001614:0
Ideal exit: 9 Sept 2024 (T+270)
5,000 shares@ US$26.9311.7% of flowAmerican Depositary SharesSEC:0000905148-23-001471:0
Ideal exit: 12 Aug 2024 (T+270)
15,900 sharesAmerican Depositary SharesSEC:0000905148-23-000761:0
13 of 13 declarations
About Smiley Joshua L
Smiley Joshua L. has an unspecified role at Zai Lab Ltd. His involvement in the company contributes to its strategic and operational objectives. Zai Lab is a biopharmaceutical company focused on developing innovative treatments for serious diseases.
